Tirzepatide-Induced Liver Injury: A Rare Complication
AACE Endocrinology and Diabetes · 2026-03 · 13 (2) · 193-197
DOI: 10.1016/j.aed.2025.11.009 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-03. Verfasst von Lauren D Spaeth und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, OhioHealth Riverside Methodist Hospital, Columbus, Ohio. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Objective: Tirzepatide is widely prescribed and generally considered safe. The objective of this report is to describe a patient with tirzepatide-induced liver injury and increase awareness of this rare complication. Case Report: A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly. She previously received semaglutide and liraglutide (total 7 years) without hepatotoxicity. Isolated right upper quadrant abdominal tenderness was present. Alanine transaminase and aspartate transferase rose from mildly elevated to 1562 U/L and 1466 U/L (normal 0-35 U/L), respectively, in 24 hours, disproportionately versus alkaline phosphatase and bilirubin. Abdominal/pelvic computed tomography scan showed a mildly dilated common bile duct post cholecystectomy. Right upper quadrant ultrasound demonstrated fatty infiltration, confirmed by magnetic resonance cholangiopancreatography. Acute hepatitis panel, acetaminophen level, ceruloplasmin, liver/kidney microsome type 1 Ab, antimitochondrial antibody, α-1-antitrypsin, and alpha-fetoprotein tumor marker were normal. Following drug discontinuation, liver enzymes normalized after 24 days. Home medications were resumed except for tirzepatide, and aminotransferases remained normal at 3 months.
Discussion
Presentations of tirzepatide-induced liver injury include asymptomatic elevation of aminotransferases, nausea, vomiting, and abdominal pain, or, although extremely rare, hepatic failure. Risk factors and pathogenesis are undetermined.
Conclusion
This case documents hepatocellular injury specific to tirzepatide despite previous tolerance of glucagon-like peptide-1 receptor agonist therapy. Clinician awareness is important since initial symptoms may be mild and attributed to common gastrointestinal side effects associated with tirzepatide. Early diagnosis and drug discontinuation resulted in resolution. If unrecognized, although rare, severe hepatic dysfunction with associated complications can result.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, OhioHealth Riverside Methodist Hospital, Columbus, Ohio.
- Department of Internal Medicine, Division of Endocrinology, OhioHealth Riverside Methodist Hospital, Columbus, Ohio.
Zitieren
APA
Spaeth, L. D., Jordan, K. M., Barlow, M. P., & Cottrell, D. A. (2026). Tirzepatide-Induced Liver Injury: A Rare Complication. AACE Endocrinology and Diabetes, 13(2), 193-197. https://doi.org/10.1016/j.aed.2025.11.009
Vancouver
Spaeth LD, Jordan KM, Barlow MP, Cottrell DA. Tirzepatide-Induced Liver Injury: A Rare Complication. AACE Endocrinology and Diabetes. 2026;13(2):193-197. doi:10.1016/j.aed.2025.11.009
BibTeX
@article{Spaeth2026,
author = {Spaeth, Lauren D and Jordan, Kim M and Barlow, Mariah P and Cottrell, Daryl A},
title = {Tirzepatide-Induced Liver Injury: A Rare Complication},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {2},
pages = {193--197},
doi = {10.1016/j.aed.2025.11.009}
}
EUVIMED